United States-based Dicerna Pharmaceuticals has submitted an
investigational new drug application to the US Food and Drug Administration for its DCR-PH1 therapeutic candidate, it was reported yesterday.
United States-based Valor Biotherapeutics has received approval for an
investigational new drug application for its lead product candidate, IGN002, a new class of biotherapeutics, from the US Food and Drug Administration, it was reported yesterday.
M2 EQUITYBITES-August 4, 2015-Mundipharma EDO's
investigational new drug for EDO-S101 accepted for review by US FDA
M2 PHARMA-July 15, 2015-The US FDA accepts Blueprint Medicines'
investigational new drug application for Phase I clinical trials of BLU-554 and BLU-285
M2 EQUITYBITES-July 15, 2015-The US FDA accepts Blueprint Medicines'
investigational new drug application for Phase I clinical trials of BLU-554 and BLU-285
M2 EQUITYBITES-March 31, 2015-China Food and Drug Administration agrees to review of WuXi MedImmune's
investigational new drug application for new anti-IL6
M2 PHARMA-March 31, 2015-China Food and Drug Administration agrees to review of WuXi MedImmune's
investigational new drug application for new anti-IL6
M2 EQUITYBITES-February 6, 2015-Sangamo BioSciences submits
investigational new drug application for SB-BCLmR-HSPC to US FDA
